Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on X:
“Updated results confirm Pembrolizumab plus CRT as the new standard in locally advanced cervical cancer!
- 32% reduced progression risk
- 40% reduced PFS2 risk
- 33% reduced death risk
3-year OS: 82.6% vs 74.8%
3-year PFS: 62.7% vs 54.5%”
More posts featuring Elvina Almuradova.